scispace - formally typeset
Search or ask a question
JournalISSN: 1972-2680

Journal of Infection in Developing Countries 

Open Learning on Enteric Pathogens
About: Journal of Infection in Developing Countries is an academic journal published by Open Learning on Enteric Pathogens. The journal publishes majorly in the area(s): Medicine & Population. It has an ISSN identifier of 1972-2680. It is also open access. Over the lifetime, 2844 publications have been published receiving 41611 citations. The journal is also known as: The Journal of infection in developing countries & JIDC.


Papers
More filters
Journal ArticleDOI
TL;DR: A brief history of bacteriophages and clinical studies on their use in bacterial disease prophylaxis and therapy are described and the advantages and disadvantages of bacter iophages as therapeutic agents in this regard are discussed.
Abstract: The emergence of multiple drug-resistant bacteria has prompted interest in alternatives to conventional antimicrobials. One of the possible replacement options for antibiotics is the use of bacteriophages as antimicrobial agents. Phage therapy is an important alternative to antibiotics in the current era of drug-resistant pathogens. Bacteriophages have played an important role in the expansion of molecular biology and have been used as antibacterial agents since 1966. In this review, we describe a brief history of bacteriophages and clinical studies on their use in bacterial disease prophylaxis and therapy. We discuss the advantages and disadvantages of bacteriophages as therapeutic agents in this regard.

430 citations

Journal ArticleDOI
TL;DR: It will be important to develop point-of-care devices to aid clinicians in stratifying elderly patients as early as possible to determine the potential level of care they will require to improve their chances of survival from COVID-19 disease.
Abstract: As of 28 February 2020, Italy had 888 cases of SARS-CoV-2 infections, with most cases in Northern Italy in the Lombardia and Veneto regions. Travel-related cases were the main source of COVID-19 cases during the early stages of the current epidemic in Italy. The month of February, however, has been dominated by two large clusters of outbreaks in Northern Italy, south of Milan, with mainly local transmission the source of infections. Contact tracing has failed to identify patient zero in one of the outbreaks. As of 28 February 2020, twenty-one cases of COVID-19 have died. Comparison between case fatality rates in China and Italy are identical at 2.3. Additionally, deaths are similar in both countries with fatalities in mostly the elderly with known comorbidities. It will be important to develop point-of-care devices to aid clinicians in stratifying elderly patients as early as possible to determine the potential level of care they will require to improve their chances of survival from COVID-19 disease.

340 citations

Journal ArticleDOI
TL;DR: This review summarizes the current knowledge on virology, epidemiology, clinical manifestation, laboratory diagnostics, treatment and prevention of hantaviruses and hantviral infections.
Abstract: Hantaviruses have the potential to cause two different types of diseases in human: hemorrhagic fever with renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS). HFRS, initially described clinically at the turn of the 20th century, occurs endemically in the Asian and European continents, while HPS, recognized as a clinical entity since 1993, represents the prototype of emerging diseases occurring in the Western hemisphere. Approximately 150,000 to 200,000 cases of HFRS are hospitalized each year world wide, with most of the cases occurring in the developing countries. The case fatality rate of HFRS varies from <1% to 12% depending on the viruses. Although HPS is much smaller in number than HFRS, with approximately 200 HPS cases per year in the Americas, the average case fatality rate is 40%. The reported cases of hantaviral infection is increasing in many countries and new hantavirus strains have been increasingly identified worldwide, which constitutes a public health problem of increasing global concern. Hantaviral infection might be underestimated due to its asymptomatic and non-specific mild infection, and the lack of simple standardized laboratory diagnostics in hospitals, especially in the developing countries. This review summarizes the current knowledge on virology, epidemiology, clinical manifestation, laboratory diagnostics, treatment and prevention of hantaviruses and hantaviral infections.

214 citations

Journal ArticleDOI
TL;DR: High levels of ESBL producers among gram negative CA-uropathogens was seen in India, and the alarming rate of resistance to ciprofloxacin, SXT and amoxicillin precludes the use of these commonly used antibiotics for empiric treatment of CA-UTI in India.
Abstract: Background: Empiric treatment of community-acquired urinary tract infections (CA-UTI) is determined by the antibiotic sensitivity patterns of uropathogens in a population. This study was conducted to determine patterns of resistance amongst CA-uropathogens in India, to help establish local guidelines on treatment of CA-UTI. Methodology: 531 consecutive positive urine cultures taken from adult non-pregnant females attending outpatient clinics of five hospitals in Delhi, India, were analysed. Sensitivity testing was done for ciprofloxacin, trimethoprim-sulphamethoxazole (SXT), amoxicillin, amoxicillin-clavulanate, amikacin, nitrofurantoin, piperacillin-tazobactam and meropenem in each isolate. Results: E. coli comprised 68%; Klebsiella 16.9%; Proteus 5.5%; Enterobacter 5.3%; Staphylococcus saprophyticus 2.8%; and others 1.5% of the isolates. Furthermore, 26.9% of the gram negative isolates were ESBL producers. Antibiotic sensitivity of all the gram negative organisms showed that 35.8% were sensitive to ciprofloxacin; 30% to SXT; 17.7% to amoxicillin; 41.6% to amoxicillin/clavulanate; 75.6% to amikacin; 65.7% to nitrofurantoin; 90.2% to piperacillin-tazobactam; and 100% to meropenem. Conclusion: High levels of ESBL producers among gram negative CA-uropathogens was seen in our country. This, along with the alarming rate of resistance to ciprofloxacin, SXT and amoxicillin, precludes the use of these commonly used antibiotics for empiric treatment of CA-UTI in India.

205 citations

Journal ArticleDOI
TL;DR: Education interventions are needed to promote prudent use of antibiotics among the public to serve as baseline data for future studies within a government hospital setting in Malaysia.
Abstract: Introduction: Public knowledge and attitudes towards antibiotics play a vital role in the success of the treatment process. This study aimed to assess public knowledge and attitudes toward antibiotic usage which could serve as baseline data for future studies within a government hospital setting in Malaysia. Methodology: A self-administered cross-sectional survey involving 408 respondents was conducted using a validated questionnaire at an outpatient pharmacy department in Penang Hospital, Malaysia, from February to March 2009. Results: Nearly 55% of the respondents had a moderate level of knowledge. Three quarters of the respondents (76.7%) could correctly identify that antibiotics are indicated for the treatment of bacterial infections. However, 67.2% incorrectly thought that antibiotics are also used to treat viral infections. About 59.1% of the respondents were aware of antibiotic resistance phenomena in relation to overuse of antibiotics. With regard to attitudes, 38% believed that taking antibiotics when having cold symptoms could help them to recover faster, while 47.3% expected antibiotics to be prescribed for common cold symptoms. Age, race and educational level were among the demographic characteristics significantly associated with knowledge and attitudes toward antibiotic use. Poor level of knowledge was found in less than one-third of the respondents whereas more than one-third of the respondents wrongly self-medicate themselves with antibiotics once they have a cold. Conclusion: Educational interventions are needed to promote prudent use of antibiotics among the public.

191 citations

Performance
Metrics
No. of papers from the Journal in previous years
YearPapers
2023121
2022268
2021104
2020260
2019192
2018197